Supplementary Figure 13 from Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Samira JaegerAna IgeaRodrigo ArroyoVíctor AlcaldeBegoña CánovasModesto OrozcoÁngel R. NebredaPatrick Aloy
0
Citation
0
Reference
10
Related Paper
Abstract:
<p>Distribution of DCI values (DCI20 to DCI80) ranging from 20 to 80% of proliferation inhibition (IC20 to IC80) for DC01 to DC10.</p>Keywords:
Cancer drugs
Cancer drugs
Cite
Citations (0)
Cite
Citations (0)
Rectal administration
Drug Administration
Cite
Citations (0)
Cancer surgery
Cite
Citations (0)
Female breast cancer recently surpassed lung cancer and became the most commonly diagnosed cancer worldwide. As per the recent data from WHO, breast cancer accounts for one out of every 8 cancer cases diagnosed among an estimated 2.3 million new cancer cases. Breast cancer is the most prevailing cancer type among women causing the highest number of cancer-related mortality. It has been estimated that in 2020, 68,5000 women died due to this disease. Breast cancers have varying degrees of molecular heterogeneity; therefore, they are divided into various molecular clinical sub types. Recent reports suggest that type 2 diabetes (one of the common chronic diseases worldwide) is linked to the higher incidence, accelerated progression, and aggressiveness of different cancers; especially breast cancer. Breast cancer is hormone-dependent in nature and has a cross-talk with metabolism. A number of antidiabetic therapies are known to exert beneficial effects on various types of cancers, including breast cancer. However, only a few reports are available on the role of incretin-based antidiabetic therapies in cancer as a whole and in breast cancer in particular. The present review sheds light on the potential of incretin based therapies on breast cancer and explores the plausible underlying mechanisms. Additionally, we have also discussed the sub types of breast cancer as well as the intricate relationship between diabetes and breast cancer.
Incretin
Cite
Citations (13)
Cancer drugs
Cite
Citations (0)
Abstract Background A growing number of women newly diagnosed with breast cancer have survived a previous cancer. Although little is known about their prognosis, this population is frequently excluded from clinical trials. Additional evidence about the survival of this population is needed, so that trial sponsors and investigators can create evidence-based trial eligibility criteria. Among women newly diagnosed with breast cancer, we examined the impact of previous cancer on overall and cancer-specific survival. Methods This population-based cohort study included patients age ≥66 years and diagnosed with breast cancer between 2005-2015 in linked SEER-Medicare data. Separately by breast cancer stage, we estimated overall survival using Cox regression and cause-specific survival using competing risk regression for women with and without previous cancer, adjusting for numerous covariates and competing risk of death from previous cancer, other causes, or the incident breast cancer. Results Of 138,576 women diagnosed with incident breast cancer, 10,822 (8%) had a previous cancer of another organ site. Many of these (n=5,014, 46.3%) were diagnosed ≤5 years of breast cancer. For all breast cancer stages except IV in which there was no significant survival difference, women with vs. without previous cancer had worse overall survival. This survival disadvantage was driven by deaths due to the previous cancer and other causes. In contrast, women with previous cancer generally had favorable breast-cancer specific survival; however this varied somewhat by stage and over time. Conclusions Many women newly diagnosed with breast cancer are already cancer survivors. These women had generally worse overall survival, worse survival from other causes, but their disease-specific survival varied depending on their breast cancer stage and over time. Citation Format: Sandi L Pruitt, Hong Zhu, Daniel Heitjan, David E Gerber, Bhumika Maddineni, Danyi Xiong, Ethan Halm, Caitlin Murphy. Survival among female breast cancer patients who have survived a previous cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS11-31.
Relative survival
Cite
Citations (0)
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2012.42.1677 Journal of Clinical Oncology - published online before print May 7, 2012 PMID: 22565000 Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics? Matthew MartinxMatthew MartinSearch for articles by this author Richard MaraisxRichard MaraisSearch for articles by this author Show More The Institute of Cancer Research, London, United KingdomThe Paterson Institute for Cancer Research, Manchester, United Kingdom https://doi.org/10.1200/JCO.2012.42.1677 First Page Full Text PDF Figures and Tables © 2012 by American Society of Clinical Oncology
Clinical Oncology
Cite
Citations (53)
Among 432 women with primary breast cancer, six (1.4%) were diagnosed as having gastrointestinal cancer more than six months after operation for the breast cancer. This paper presents these six cases. The patients ranged from 56 to 78 years of age at the time of breast cancer surgery, and the interval after surgery until diagnosis of the second cancer ranged from 7 months to 5 years 1 month. The second cancer was gastric cancer in 3, esophageal cancer in 2, and hepatic cancer in 1. All of the 6 patients had received postoperative adjuvant chemotherapy for breast cancer. The most frequent histological type of breast cancer was solid-tubular carcinoma (3 patients). Three patients died, due to the second cancer, 4 days, 2 months, and 6 months, respectively, after diagnosis of the second cancer, and the other patients are alive 2, 3, and 4 years after diagnosis. The Japanese literature regarding multiple cancer among breast cancer patients is reviewed. It is concluded that care should be taken to examine breast cancer patients with gastrointestinal symptoms, which are likely to be dismissed as a side effect of postoperative chemotherapy.
Gastrointestinal cancer
Adjuvant Chemotherapy
Cite
Citations (0)
One of the great challenges in human health is the threat of cancer, which is a major lethal disease. Therefore, it is necessary to design new drugs to cure it. However, despite the advanced technologies and enormous efforts, the average time of novel drug discovery is still eight years, which is much longer than our expected. In addition, an important step in drug discovery is the identification and confirmation of drug targets. In the study, the important features of human protein-protein interaction (PPI) network of the drug targets aiming to cancer were identified. First, the corresponding disease of US FDA approved drugs were confirmed and the cancer drugs were selected. Second, an approach based on artificial intelligence algorithm was applied for identifying significant features differencing the therapeutic target between cancer drugs and non-cancer drugs. The result that is the selected features clarified the important factors indicating cancer drugs and could provide a new direction for identifying the therapeutic targets aiming to the cancer drug.
Cancer drugs
Identification
Cite
Citations (0)